Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines.
We have previously shown a critical role of prolactin (PRL) during maturation and anti-tumor effects of murine natural killer (NK) cells in vitro and in vivo. We extended that study by exploring the ability of human NK cell lines (NK-92 and YT cell) to express PRL receptor (PRL-R) and to respond to PRL stimulation in vitro. Both human NK cell lines constitutively expressed PRL-R on membrane and mRNA transcripts, NK-92 cells contained higher level of PRL-R than YT cells, which correlated to the enhanced capacity of the cells to proliferate and to lyse target cells in response to PRL stimulation in the presence of trace amount of IL-2 or IL-15 in vitro. Two differences between IL-2 and IL-15 in functioning on human NK cells were for the first time observed. PRL synergized with IL-15 to improve proliferation of NK cells in a dose-dependent manner without double peak manifesting like IL-2. Although PRL enhanced the cytotoxicity of IL-2 or IL-15 activated NK cells, it exerted the function through up-regulating gene expression of perforin without influence of FasL in IL-2-stimulated NK cells, while in IL-15-stimulated NK cells, PRL did the function through up-regulating gene expression of both perforin and FasL but not IFN-gamma. PRL increased expressions of IL-2Ralpha on membrane and of IL-2 mRNA in cells, indicating that PRL up-regulated NK cell function by improving positive feedback between IL-2 and IL-2R. The similar results were also observed in network between IL-15 and IL-15R. These data indicate a potential role of PRL in human NK cell modulation.
Sun
Rui
R
School of Life Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China.
Li
Ai Ling
AL
Wei
Hai Ming
HM
Tian
Zhi Gang
ZG
D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000235:genetics; D019409:Interleukin-15 / Q000235:genetics / Q000494:pharmacology / Q000502:physiology; D007376:Interleukin-2 / Q000235:genetics / Q000494:pharmacology / Q000502:physiology; D007694:Killer Cells, Natural / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000235:genetics; D008856:Microscopy, Fluorescence; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D011388:Prolactin / Q000494:pharmacology* / Q000502:physiology; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011981:Receptors, Prolactin / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
C505661:FASLG protein, human; D053222:Fas Ligand Protein; C508024:IL15RA protein, human; D019409:Interleukin-15; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2; D011981:Receptors, Prolactin; D054353:Perforin; D012313:RNA; D007371:Interferon-gamma; D011388:Prolactin